hances PPAR ligand-mediated regulation whereas a mutant form devoid of histone acetylase activity blocks the response of the promoter to fatty acids. Conversely, histone deacetylase-1 blunts MyoDdependent expression of the UCP3 promoter and reduces PPAR-dependent responsiveness. A mutated form of MyoD unable to be acetylated has a lower transactivation capacity on the human UCP3 promoter with respect to wild-type MyoD. It is concluded that MyoD and PPAR-dependent pathways mediate human UCP3 gene regulation and that acetylase activity elicited by coregulators is implicated in the functional interaction between these regulatory pathways. Therefore the convergence of MyoD and PPAR-dependent pathways provides a molecular mechanism for skeletal muscle specificity and fatty acid regulation of human UCP3 gene. U NCOUPLING PROTEIN-3 (UCP3) is a member of the mitochondrial carrier superfamily, which shares 56% and 73% identity to UCP1 and UCP2, respectively (1, 2) . UCP3 differs from the other two mainly because of its predominant expression in skeletal muscle in humans (3) and in skeletal muscle and brown fat in rodents, whereas UCP1 is present only in brown fat and UCP2 is almost ubiquitous. Several studies have shown that UCP3, when overexpressed in yeast or mammalian muscle cells, causes a reduction in the mitochondrial membrane potential that is consistent with a potential role as an uncoupler (4, 5) . Thus, when UCP3 is overexpressed in skeletal muscle of transgenic mice, it increases metabolic rate, mitochondrial protein leak, and lipid oxidation (6) . However, it is not clear whether this effect is a specific result of UCP3 activity or nonspecific owing to overexpression of a mitochondrial membrane protein (7) . Moreover, mitochondria from mice with a targeted disruption of the UCP3 gene show reduced mitochondrial proton leak (8, 9) and increased efficiency in ATP production (10) . However, no major impact in overall metabolism at the whole-body level is observed.
Accumulating evidences indicate that UCP3 contributes to lipid handling by the skeletal muscle rather than uncoupling mitochondrial oxidative phosphorylation. There is preferential fatty acid oxidation with respect to glucose in human myotubes overexpressing UCP3 (11) and a tendency to an impaired fatty acid oxidation in UCP3 knockout mice (12) . In humans, a splice-site mutation in the UCP3 gene that prevents the synthesis of the full-length UCP3 protein resulted in impaired fat oxidation (13) , although other studies did not confirm these findings (14) . On the other hand, a single nucleotide (T to C) polymorphism in the 5Ј-proximal noncoding region of the human UCP3 gene has been associated with disturbances in fat accumulation in several human populations (15, 16) .
The preferential expression of UCP3 in the skeletal muscle is of interest because this tissue is an important site of energy homeostasis in mammals. UCP3 gene transcription in skeletal muscle is highly regulated in relation to cell differentiation. In cultured muscle cells, either from myogenic cell lines or primary cultures of human myotubes, differentiated in vitro UCP3 mRNA expression is induced in association with differentiation although at much lower levels than in muscle in vivo (17) . UCP3 gene transcription is highly sensitive to several metabolic and hormonal signals, especially those related to fatty acid availability. In rodents, situations in which circulating free fatty acid levels are up-regulated, such as starvation, postnatal development, exercise, and high-fat diets (18) , are associated with up-regulation of UCP3 mRNA expression whereas, when free fatty acid levels decrease, as in lactation, UCP3 mRNA levels are low (19) . In this sense, lipid infusion to human volunteers causes a significant up-regulation of the UCP3 gene (20) . There is a strong interaction between myogenic and fatty acid-dependent regulation of UCP3 gene expression. This interaction is highlighted during mouse development when the UCP3 gene transcription is switched on specifically in skeletal muscle only after birth and under the stimulus of the initiation of suckling and the appearance of high levels of free fatty acids in the circulation (21) .
Accumulating evidence indicates that fatty acids may act through peroxisome proliferator-activated receptors (PPARs) to induce UCP3 gene expression (21) although other events such as activation of AMP-activated protein kinase may also contribute to this regulation (22) . Single injections of PPAR␣ or PPAR␣ ϩ ␦ activators into mice increase UCP3 mRNA levels in skeletal muscle, especially in physiological situations in which basal levels of circulating free fatty acids are low (starved neonates, lactating dams) (19, 21) . In contrast, the capacity of PPAR␥ activators to induce UCP3 gene expression in vivo depends on the physiological situation, thus suggesting an indirect mechanism of action (19, 23, 24) . In cell cultures, PPAR␦ activation has been claimed to be the main inducer of UCP3 mRNA expression, probably due to the lack of expression of PPAR␣ in myogenic cells differentiated in culture (25) . However, the molecular mechanisms driving UCP3 gene transcription in skeletal muscle and in response to fatty acids have not been established.
In the present work, we report that fatty acids induce the UCP3 gene transcription through a PPAR-responsive site, we define a novel site for the action of MyoD, which is required for UCP3 promoter activity and PPAR-dependent responsiveness, and we propose a molecular mechanism for functional interaction of fatty acid-and MyoD-dependent activation based on the action of p300 protein (p300) coactivation and histone acetylation activity.
RESULTS

Fatty Acid Activation of the Human UCP3 Promoter through PPAR␣ and PPAR␦; MyoD Is Required for PPAR-Dependent Activation
To study the basis for fatty acid-dependent regulation of the muscle-specific UCP3 gene, transient transfection experiments were performed using a construct containing 1.5 kb of the 5Ј-region of the human UCP3 gene fused to luciferase and the L6 myogenic cell line. These cells do not express endogenous MyoD and can undergo myogenic differentiation, thanks to the redundant role of other myogenic factors such as . Basal expression of UCP3 is very low in L6 cells, even when differentiated, and they are highly responsive to transfected MyoD (17) . As the human UCP3 promoter has been demonstrated to be highly sensitive to MyoD (17) , the effects of fatty acids were determined in the presence of cotransfected MyoD. We also studied the influence of PPAR subtype cotransfection in UCP3 transcriptional regulation. In the absence of cotransfected MyoD, the human UCP3 promoter was not sensitive either to oleic acid or to other PPAR activators (Fig. 1A) . MyoD cotransfection increased UCP3 promoter activity, but oleic acid alone had no significant effect. However, when either PPAR␣ or PPAR␦ (but not PPAR␥) was cotransfected, the UCP3 promoter was induced by oleic acid. Similar results were found for linoleic acid (not shown). Cells were then cotransfected with PPAR subtypes in the presence of MyoD and exposed to agonists with a range of PPAR-subtype specificities. Then, 10 M Wy14,643, which is specific for PPAR␣ activation, stimulated the UCP3 gene promoter activity only when PPAR␣ was cotransfected. Bezafibrate, which activates both PPAR␣ and PPAR␦, induced the UCP3 promoter when either of the two receptors was cotransfected. Even in the presence of the specific PPAR␥ activator rosiglitazone and the cotransfected PPAR␥ receptor, the UCP3 promoter was not induced. To ensure that the lack of response to PPAR␥-dependent activation was not due to impaired expression of the receptor, the three PPARs were transfected to L6 cells, and a specific antibody against each PPAR subtype was used to detect the protein. PPAR␥ as well as PPAR␣ and -␦ were highly expressed in the cells after transfection (Fig. 1B) . Moreover, a construct containing the PPAR-response element (PPRE) from the apolipoprotein AII gene upstream from the basal thymidine kinase promoter was sensitive to liganddependent activation of the three PPAR subtypes, including PPAR␥ (Fig. 1C) . Therefore, it is concluded that fatty acids can activate the UCP3 gene promoter through PPAR␣ or PPAR␦ depending on MyoD. It is worth noting that the response to oleate through PPAR␣ or PPAR␦ and the lack of responsiveness to PPAR␥ activation was similar when a construct containing a longer sequence of the 5Ј region (Ϫ2903 hUCP3-Luc) was tested (data not shown). A, L6 cells were cotransfected with Ϫ1588 hUCP3-Luc either with or without MyoD plus or minus PPAR␣, PPAR␦, or PPAR␥-expression vectors. When indicated, cells were treated for 24 h with 500 M oleic acid (oleic), 10 M Wy14,643 (Wy), 100 M bezafibrate (Bz), or 10 M Rosiglitazone (Rosi). Basal expression of Ϫ1588 hUCP3-Luc is set to 1. Results are the mean Ϯ SEM of at least three independent experiments performed in triplicate. All samples cotransfected with MyoD-expression vectors show significantly higher differences than noncotransfected ones (P Ͻ 0.001). Significant differences due to addition of the agonists with respect to their relative controls are shown as ࡗ, P Ͻ 0.05; or ࡗࡗ, P Ͻ 0.01. B, Western blot analysis of the expression of PPARs in L6 cells after transfection. PPAR␣, PPAR␦, or PPAR␥ expression vectors were transfected when indicated as ϩ and 20 g of nuclear protein extracts were separated in a polyacrylamide gel as described in Materials and Methods. Specific antibodies against each PPAR subtype were used to detect the protein. C, Functional analysis of the overexpressed receptors. The plasmid containing three copies of the PPRE from mouse apolipoprotein AII gene upstream TK-Luciferase (250 ng) were cotransfected with 50 ng of the PPAR␣, -␦, or -␥ expression vectors to L6 cells. Cells were treated as in panel A. Significant differences due to addition of the agonists (at doses indicated above) with respect to the control are shown as *, P Ͻ 0.05.
To characterize the effects of MyoD on PPARdependent activation on the UCP3 promoter, doseresponse experiments were performed. Effects of different amounts of MyoD over the Ϫ1588 hUCP3-Luc construct and the influence on PPAR-dependent responsiveness were determined (Fig. 2) . The UCP3 promoter showed a dose-dependent activation by MyoD and the cotransfection with 0.3 g of PPAR␣ per plate did not affect significantly the dose-response curve for MyoD. Although low amounts of MyoD were already permissive for PPAR␣ ligand-mediated activation by Wy14,643, PPAR␣ ligand-mediated activation of the UCP3 promoter increased with the amount of MyoD. Previous work in our laboratory described a DR-1 site at the position Ϫ71/Ϫ59 of the 5Ј-flanking region of the human UCP3 gene (Fig. 3A) as the element responsible for the transcriptional activation of the UCP3 promoter by retinoic acid (17) . Because DR-1 elements may act as promiscuous sites of binding nuclear receptors, we investigated the role of this DR-1 on PPAR-dependent activation. Promoter constructs that contain point mutations in either one halfsite or both half-sites of the DR-1 were cotransfected with MyoD and PPAR␣-expression vectors and treated with Wy14,643 (Fig. 3B) . The sensitivity of Ϫ1588mut1DR1hUCP3-Luc and Ϫ165mut1DR1hUCP3-Luc (mutant constructs with one mutated half-site) to Wy14,643 decreased by 70% when compared with the wild-type construct. Mutation of both half-sites of the DR-1 (Ϫ165mutDR1hUCP3-Luc), or complete deletion of the DR-1 (Ϫ60 hUCP3-Luc), caused even greater reduction of PPAR␣-dependent activation. The same was observed for PPAR␦-mediated responsiveness to bezafibrate (data not shown). Therefore, it is concluded that this DR-1 at position Ϫ71/Ϫ59 mediates the response of the promoter to PPAR agonists.
The T-to-C polymorphism in the UCP3 gene is placed in the adjacent region (4 bp 3Ј from the second half-site) to the DR-1 (see asterisk in Fig. 3A) . A mutated version of our parental UCP3 promoter construct in which T was changed to C was designed and studied for PPAR-dependent responsiveness. There was no difference in the behavior of the UCP3 promoter in response to Wy14,643 in the presence of cotransfected PPAR␣. The same results were found for PPAR␦-dependent activation (not shown).
EMSAs were performed to determine whether PPAR␣ present in muscle nuclear extracts binds to the DR-1 sequence (Fig. 3C) . As a labeled probe we used a oligonucleotide corresponding to the Ϫ79 to Ϫ50 region of the human UCP3 gene. After incubation of the labeled double-stranded probe with nuclear protein extracts, a characteristic pattern of DNA-protein binding complexes was formed. NS was a nonspecific band as determined by the lack of competition when incubated with a 100-fold excess of cold oligonucleotide. The antibody against PPAR␣ prevented the formation of bands a and b, which otherwise were unaltered when the antibody against CCAAT enhancer binding protein (C/EBP␣) (negative control) was used. Incubation of the extracts in the presence of 100 M Wy14,643 did not strengthen the intensity of bands a and b (data not shown). In conclusion, both bands a and b are formed by protein-DNA complexes containing PPAR␣.
In Vivo Gene Transfer Indicates a Major Role for the DR-1 PPAR-Responsive Region of UCP3 Gene Promoter in Mediating Fatty Acid Responsiveness
To investigate the relevance of this DR-1 in the responsiveness to fatty acids in vivo, somatic gene transfer to skeletal muscle was performed as reported in Materials and Methods. The plasmid constructs depicted on the left of Fig. 4 (wild type, DR-1-mutated and empty plasmid) were analyzed. The experiments were performed in neonatal mice, a situation in which mouse UCP3 gene expression is known to be dramatically up-regulated due to the rise in circulating fatty acids as a consequence of milk intake (21) . The injected promoterless plasmid (pGL3-basic) showed negligible luciferase activity. The wild-type construct showed a significant activity, and the point-mutated version in the DR-1 showed a dramatic reduction in activity with respect to the parental construct. These findings indicate that the DR-1 PPAR-responsive ele- ment, in the proximal region of the human UCP3 promoter, is involved in fatty acid-dependent regulation in vivo.
MyoD Activates the Human UCP3 Promoter through a Proximal Region Next to a Transcription Initiation Site
To further characterize the molecular mechanisms responsible for transcriptional regulation of UCP3 gene promoter, we searched for elements mediating MyoDdependent activation (Fig. 5 ). In agreement with previous findings (17) , results obtained from constructs containing 1588 bp of the promoter (Ϫ1588 hUCP3-Luc) or 165 bp (Ϫ165 hUCP3-Luc) showed similar levels of induction when cotransfected with MyoD expression vector, thus indicating that the sequence responsible for MyoD-dependent activation is within Ϫ165 bp of the promoter. Computer-based analysis of the sequence from Ϫ165 to the first exon of human Squares show an alignment of half-sites for a DR-1. Asterisk indicates a potential change from T to C corresponding to the polymorphism described in the UCP3 promoter in the human (15, 16) . B, Deletion and point mutation analysis of the human UCP3 promoter in response to the PPAR␣ agonist Wy14,643 (10 M) in the presence of cotransfected MyoD and PPAR␣ expression vectors. Results represent means Ϯ SEM of three to five independent experiments, and they are percentages with respect to the maximum effect achieved on the Ϫ1588 hUCP3-Luc (100%). C, EMSA to study the interaction of PPAR␣ on the DR-1 at position Ϫ71 to Ϫ59. A double-stranded oligonucleotide corresponding to Ϫ79/Ϫ50 region of the human UCP3 promoter was used as a labeled probe. Nuclear protein extracts (5 g) from mouse skeletal muscle were incubated as described in Materials and Methods and, when indicated, antibodies against PPAR␣ and C/EBP␣ (negative control) were added. a, b, and ns denote the retarded complexes formed.
UCP3 promoter for sequence elements potentially capable of binding MyoD showed a unique canonical Ebox (CANNTG), found at position Ϫ106 to Ϫ101. Mutation analysis of this Ebox site (Ϫ165mutEbox-hUCP3-Luc) demonstrated no reduction in luciferase activity in response to MyoD when compared with its control (Ϫ165 hUCP3-Luc).
Further deletions in the promoter indicated that the sequence responsible for the MyoD action was between Ϫ60 to ϩ47 because Ϫ60 hUCP3-Luc retained most of MyoD-dependent responsiveness although it was completely insensitive to the PPARdependent pathway. Sequence analysis of the proximal region of the human UCP3 promoter indicated that the sequence surrounding the C-to-T polymorphism (GCCTGTGT) was similar to a recently reported noncanonical element in the human acetyl-CoA carboxylase ␤ promoter (GCCTGTCA) mediating MyoD responsiveness (27) . Only when the T was present, did the sequence of the UCP3 promoter fit the MyoD-responsive element in the acetylCoA carboxylase ␤ promoter. However, results indicated that the capacity of MyoD to transactivate the C or T versions of the UCP3 promoter did not show statistically significative differences (Fig. 5) .
Further sequence analysis of the proximal UCP3 promoter region for potential sites of MyoD responsiveness was performed. This led to the identification, at position Ϫ29 to Ϫ9, close to the transcriptional start site, of two consecutive noncanonical Eboxes (CAN-NAG sequence) and an identical third box separated from the other two by three bases. Site-directed mutagenesis changed three CAs to TTs on the three Ebox-like sequences, and transcriptional induction by MyoD was assessed. Results with this mutant construct, Ϫ165mutCAhUCP3-Luc, showed 80% reduction when cotransfected with MyoD compared with its control (Ϫ165 hUCP3-Luc). This result indicates that Reporter gene constructs depicted on the left (100 g) were combined with 10 g of pRL-CMV and directly injected into hindlimb leg muscle of neonatal mice just after birth (before initiation of suckling). Pups were kept with their mothers and 72 h later muscles were collected and homogenized in PLB buffer and analyzed for Firefly and Renilla luciferase activities. Results are the mean Ϯ SEM of four to six different mice. The significance is *, P Ͻ 0.05; **, P Ͻ 0.01.
Fig. 5. MyoD Action on Human UCP3 Promoter
Transcriptional activity of mutant constructs in response to MyoD. Cells were transfected with the reporter gene constructs shown on the left and with MyoD-expression vector as described in Materials and Methods. Results are expressed as percentages with respect to the activation achieved with Ϫ1588 hUCP3-Luc and are the mean Ϯ SEM of three to six different experiments. Statistical differences are shown as *, P Ͻ 0.05; and **, P Ͻ 0.01. The sequence represents the fragment from Ϫ29 to ϩ5 human UCP3 promoter containing the three CAnnAG sites. The tt are the point mutations performed in the Ϫ165mutCAhUCP3-Luc.
most of the effect of MyoD on the UCP3 gene promoter takes place through proximal noncanonical sites located close to the transcription initiation.
Binding of MyoD to the Proximal Region of the UCP3 Gene Promoter
The interaction of MyoD with the region of the UCP3 gene, which contains the three Ebox-like sequences, was established by EMSA (Fig. 6B) . Three doublestranded DNA probes were generated from the human UCP3 promoter sequence (Fig. 6A) . The first two are wild-type oligonucleotides of different sizes, and the third contains the three CAs changed to TTs (the same point-mutation tested functionally, Fig. 5 ). The Ϫ29/ϩ5 hUCP3 labeled probe, which includes the three Eboxlike sites plus the surrounding sequences to transcription initiation, was incubated with L6 nuclear extracts, which are devoid of MyoD (28) . This led to the appearance of two retarded complexes, a1 and a2. The incubation of this oligonucleotide with recombinant MyoD alone generated two complexes, b1 and b2, of differing mobility. When MyoD was added to the incubation buffer together with the nuclear extracts b1 and b2, complexes remained and a novel low-mobility band, indicated as c, appeared. It appears, therefore, that complex c is formed as a consequence of the interaction of nuclear proteins from L6 with MyoD upon this DNA region. When the shorter oligonucleotide Ϫ29/Ϫ9 hUCP3, in which the Ebox-like elements remain but sequences surrounding the transcription start site are absent, was incubated with L6 nuclear protein extracts, the retarded complexes a1 and a2 did not form. Therefore, bands a1 and a2 contain proteins that interact with the DNA sequence between Ϫ9 and ϩ5. When MyoD alone was incubated, complexes b1 and b2 were formed, similarly to those observed with the full-length probe. However, in this case the incubation of MyoD plus nuclear extracts caused only the appearance of the b1 and b2 complexes, but c did not appear. When Ϫ29/ϩ5muthUCP3 was incubated with nuclear L6 protein extracts, retarded bands a1 and a2 were formed as with the non-Ebox-mutated version. No retarded bands b1, b2, or c were observed when MyoD was added to the incubation media either alone or in combination with extracts. These findings indicate that the Ebox-like sequences are required for MyoD binding to the human UCP3 promoter sequence, that other nuclear proteins bind sites around the transcription initiation site, and that they interact with MyoD when bound to DNA.
To further examine the interaction of MyoD with the proximal region of the human UCP3 gene promoter in vivo, chromatin immunoprecipitation (ChIP) experiments were performed using human skeletal muscle cells in culture (Fig. 7) . Immunoprecipitation of protein-DNA complexes with the MyoD antibody caused a specific enrichment of the 191-bp PCR product corresponding to the Ϫ166 to ϩ26 region of the endogenous hUCP3 gene. Transfection with the MyoD expression vector increased this effect (Fig. 7A) , which is consistent with the expression of endogenous MyoD in human skeletal muscle cells and the increase in MyoD elicited by transfection with the MyoD expression vector (Fig. 7B) . To establish the involvement of the three Ebox-like sequences in the MyoD binding in vivo, ChIP experiments were performed. The Ϫ165 hUCP3-Luc or Ϫ165 mutCAhUCP3-Luc constructs were cotransfected with MyoD expression vector in L6 cells (Fig. 7C) . When cells were transfected with Ϫ165 hUCP3-Luc and immunoprecipitated with MyoD antibody, PCR amplification detected a specific enrichment in the fragment of DNA region containing the three noncanonical
p300 Histone Acetylase Activity Enhances PPARDependent Ligand Activation of the UCP3 Gene Promoter
Considering the strong functional interaction between PPAR-and MyoD-dependent pathways and the separate placement of their respective response elements in the UCP3 gene promoter, several coactivators, previously described to interact with nuclear receptors and/or MyoD, were checked for their capacity to influence MyoD and PPAR-dependent effects. When p300, P/CAF, steroid receptor coactivator-1, and Tat- interactive protein-60 kDa expression vectors were cotransfected with human UCP3 promoter reporter constructs, only p300 caused a significant effect on the behavior of the UCP3 promoter: it did not modify the effects due to transactivation by MyoD, but it enhanced the ligand-dependent activation through PPAR␣ (Fig. 8A ). p300 is a nuclear hormone receptor coactivator, and it has been shown to interact with PPAR␣ (29) and to acetylate both histones and MyoD (30) . To study the role of the acetylation activity of p300 on UCP3 promoter regulation, cotransfection experiments using a mutant form of p300 with no histone
Fig. 8. Effects of p300 and Role of Acetylation Processes on the MyoD and PPAR-Ligand Dependent Activity of the hUCP3 Promoter
A, Effects of p300, p300⌬HAT and HDAC1 on the MyoD and PPAR-ligand dependent responsiveness of Ϫ1588 hUCP3-Luc. Cotransfection experiments were performed as described in Materials and Methods and when indicated 0.3 g of p300, p300⌬HAT and/or HDAC-1 expression vectors per plate were included into the experiment. Basal expression of Ϫ1588 hUCP3-Luc is set to 1. When indicated 10 M of Wy14,643 or 100 ng/ml TSA was added to the cells for 24 h Results show the mean Ϯ SEM of at least three independent experiments done in triplicate. Statistical significance of comparison between basal levels and MyoD cotransfected cells is shown by *, P Ͻ 0.001. Comparison between cells treated with 10 M Wy14,643 with respect to its nontreated control is shown by ⌬, P Ͻ 0.01. Comparison of the effect of Wy14,643 or MyoD between different cotransfected groups is shown by ࡗ, P Ͻ 0.01; and #, P Ͻ 0.01, respectively. B, ChIP analysis of the histone H3 acetylation status at hUCP3 promoter upon activation with MyoD and PPAR␣. Chromatin cross-linking was performed using human skeletal muscle cells that were transfected or not with the MyoD and PPAR␣ expression vectors and exposed to 10 M Wy14,643 with (ϩ) or without (Ϫ) 100 ng/ml TSA for 24 h. Immunoprecipitation was performed using a specific antibody for acetylated histone H3. PCR amplification product corresponds to the 191 bp of the hUCP3 gene promoter (see Materials and Methods). Input corresponds to the 191-bp product obtained by PCR of cleared chromatin before immunoprecipitation for each experimental point. Results shown are representative of three independent experiments. acetylase activity (p300⌬HAT) were performed. As shown in Fig. 8A, p300⌬HAT did not significantly modify transactivation of the promoter by MyoD but completely blocked the induction by PPAR ligands, thus indicating that acetylation by p300 is crucial for PPARdependent activation of human UCP3.
Role of Acetylation Processes on the Control of Human UCP3 Gene Transcription
To further study the role of acetylation on the control of UCP3 gene transcription, cells were transfected with an expression vector driving histone deacetylase 1 (HDAC1), an enzyme recently implicated in silencing mammalian genes by deacetylation of histones as well as of MyoD (31, 32) . HDAC1 inhibited the capacity of MyoD to induce UCP3 promoter activity and reduced the activity of the promoter in the presence of PPAR␣ and its ligand (Fig. 8A) . The positive effects of p300 on PPAR ligand-dependent activation of the UCP3 promoter were completely suppressed when HDAC1 expression vector was cotransfected. The effects of transfected HDAC1 were due to its deacetylase activity, as treatment of cells with trichostatin A (TSA), a histone deacetylase inhibitor, eliminated the repressive effects of HDAC1. It is concluded that histone acetylase activity participates in the MyoD-and PPAR-dependent regulation of human UCP3 promoter.
To check whether the acetylation status of histones in the proximal region of the endogenous hUCP3 gene promoter was affected by gene activation elicited by MyoD and the PPAR␣-dependent pathway, ChIP assays for acetylated histone H3 were performed using human skeletal muscle cells. As shown in Fig. 8B , cotransfection with MyoD and PPAR␣ expression vectors in the presence of Wy14,643 enhanced the levels of acetylated histone H3 bound at the hUCP3 promoter. In addition, TSA treatment led to a further increase in the levels of acetylated histone H3 on the promoter.
MyoD Acetylation Is Necessary for the Full Activation of the Human UCP3 Promoter
Because p300 can acetylate not only histones but also MyoD and other transcription factors, we next tested whether the specific acetylation of MyoD was functionally relevant in the activity of the human UCP3 promoter. We performed transient transfections using a nonacetylable form of MyoD generated by direct mutagenesis from Lys-to-Arg substitutions at positions 99, 102, and 104 (MyoD-RRR), as reported previously (33) . As shown in Fig. 9 , the human UCP3 promoter activity achieved by MyoD-RRR cotransfection was 50% of that observed by wild-type MyoD. In the presence of MyoD-RRR, the activity elicited by PPAR␣ plus Wy14,643 was lower than in the presence of MyoD, although sensitivity to ligand remained. This result indicates that acetylation of MyoD is necessary for the full activity of the promoter.
DISCUSSION
Major features of UCP3 gene regulation in humans are skeletal muscle specificity and fatty acid-dependent regulation. Here we show that the human UCP3 promoter is regulated by two mechanisms consistent with this behavior: the myogenic factor MyoD is required for substantial promoter activity, and fatty acids activate the promoter. PPAR␣ or PPAR␦ are necessary to mediate fatty acid-dependent regulation. Moreover, there is a functional interaction between myogenic differentiation-dependent and fatty acid activation of the UCP3 gene, which is also evidenced by UCP3 promoter regulation: MyoD is required not only for a high UCP3 promoter activity but also for sensitivity to ligand-dependent activation of PPARs.
The sites mediating PPAR and MyoD-dependent activation were physically separated in the promoter. PPAR action occurs through a DR-1 element in the proximal promoter region that we previously reported to act also as a retinoic acid-responsive element (17) . This site was critical for fatty acid induction of the promoter in vivo, as demonstrated here by the lack of responsiveness of point-mutated constructs of the promoter directly injected to the hind limb of newborn mice under the stimulus of fatty acids coming from milk intake (21) .
The structure of this element as a DR-1 is in agreement with the characteristic alignment of PPARresponsive elements. The presence of this sequence in the UCP3 promoter was also described previously by Acin et al. (34) . However, the role of this DR-1 in mediating retinoic acid-dependent effects, not only through activation of the retinoid X receptor moiety of the PPAR/retinoid X receptor heterodimer, but also through retinoic acid receptor (17) , indicates that it behaves as a multihormonal-regulatory element in the human UCP3 gene and agrees with the DR-1 structure which, is highly permissive for multiple nuclear receptor-mediated responses.
The specific responsiveness of the UCP3 gene promoter to PPAR␣ or PPAR␦ and their respective ligands, but the lack of sensitivity to PPAR␥, is consistent with the responsiveness of the gene to physiological situations associated with increased circulating free fatty acids. A broad array of fatty acids of different lengths and saturations behave as natural activators of PPAR␣ and PPAR␦ subtypes, but PPAR␥ is less sensitive to them (35) . PPAR-response elements in mammalian genes are often highly promiscuous in response to the different PPAR subtypes, and their activation by the different PPAR subtype-dependent pathways is due to the action of specific ligands or to the expression of specific PPAR subtypes in target cells (35, 36) . However, there are also several examples of partially PPAR subtype-specific responsiveness (37), such as the present findings on the human UCP3 gene promoter. Further research will be needed to assess whether the specific sequence of the UCP3 DR-1 dictates the differential responsiveness to PPAR␣ and -␦ subtypes with respect to PPAR␥ or this is due to the particular placement of the DR-1 in the context of the UCP3 promoter structure.
Although several consensus sequences (Eboxes) have been described as putative sites for MyoD binding within the human UCP3 promoter (34), our results demonstrate that MyoD did not act in the UCP3 gene promoter through canonical Ebox elements but through a proximal region, close to the transcription initiation site, which contains degenerate Ebox elements. A similar atypical site of action for MyoD through interaction with elements close to transcription initiation has been reported for other skeletal muscle-specific genes such as skeletal myosin heavy chain IIB or acetyl CoA carboxylase-␤ (27, 38) . MyoD can interact with this region either alone or by forming complexes with other nuclear proteins in L6 cells, which are devoid of endogenous MyoD (28) . Whereas degenerate Ebox elements are required for MyoD binding and MyoD-dependent transactivation, the presence of adjacent regions close to the transcription initiation site leads to the formation of ternary complexes also containing MyoD. Thus, the MyoD is likely to interact with proteins associated with basal transcription machinery. The location of MyoD binding close to transcription initiation and the interaction with other proteins associated with this region are consistent with the high dependency of the human UCP3 promoter activity on MyoD.
Despite the separate location of PPAR and MyoD sites in the UCP3 promoter, the functional interaction between the two pathways of UCP3 promoter regulation was explored. When the effects of several coactivators known to interact with nuclear hormone receptors was determined, only p300 potentiated PPAR-ligand dependent activation. P300 has been reported to interact with and coactivate PPAR␣ (29) , and it also acetylates histones as well as MyoD, thus promoting MyoD transcriptional activity (39, 40) . The dramatic silencing of PPAR-dependent activation mediated by the nonacetylating mutant form of p300 provides evidence for the involvement of histone acetylase activity driven by p300 in the regulation of human UCP3 promoter by PPAR.
The involvement of acetylation processes in UCP3 promoter regulation was confirmed by the repressing effects of cotransfection with an expression vector for HDAC-1, which has recently been reported to modulate transcriptional activity by deacetylation, not only of histones but also MyoD (31). Moreover, transcriptional activation of the hUCP3 gene by MyoD and PPAR␣ was associated with increased acetylation status of histones bound to the promoter. These findings suggest that the transcriptionally active complex formed when PPAR interacts with ligands in the presence of MyoD involves p300 as a bridging molecule and that acetylation of histones and MyoD are important events to provide active transcription and liganddependent sensitivity to the system. The direct effect of MyoD on the promoter without adding any further acetylating coactivator is also compatible with this proposal since most of MyoD is known to be acetylated when transfected to myoblastic cells (33) . The specific role of MyoD acetylation in the UCP3 promoter activity was evidenced by the reduced transactivation capacity of a nonacetylable mutant form of MyoD. The finding that the nonacetylable form of MyoD remains partially permissive to PPARdependent activation can indicate either that other factors or histones are acetylated by p300 or that MyoD retains some activity and still binds to the same or other transcription factors despite the mutation.
In summary, we propose a tentative model for the transcriptional control of the UCP3 gene by MyoD and PPAR-dependent pathways (see Fig. 10 ). Coactivators such as p300 may provide a bridging mechanism between PPAR-dependent activation and the basal transcription machinery, which includes MyoD. Acetylation elicited by p300 or other acetylases, on MyoD and histones, would be associated with the transcriptionally active status of the gene, both in basal conditions and especially in response to PPAR-dependent activation. Present findings suggest that these mechanisms provide the molecular basis for the transcriptional regulation of the UCP3 gene by fatty acids in human skeletal muscle.
MATERIALS AND METHODS
Materials
Oleic and linoleic acids, Wy14,643 (pirinixic acid), bezafibrate, and trichostatin A were obtained from Sigma (St. Louis, MO). Rosiglitazone was a kind gift from Dr. L. Casteilla (University of Toulouse, Toulouse, France). [␣-
32 P]dCTP was from Amersham Pharmacia Biotech (Arlington Heights, IL).
Construction of Transfection Plasmids
The insertion of the fragment from Ϫ2903 to ϩ47 of the human UCP3 gene into pGL3-basic generates Ϫ2903 hUCP3-Luc and a SacI restriction, and religation generates the Ϫ1588 hUCP3-Luc construct, according to a previous report (17) . A further deletion was generated from this last construct by restriction with SacI and BglII, blunt ending, and religation, thus generating Ϫ165 hUCP3-Luc.
Point mutation constructs were generated using a QuikChange Site-directed mutagenesis kit (Stratagene, La Jolla, CA). In summary, two complementary oligonucleotides containing the desired mutations, flanked by unmodified nucleotide sequence, were synthesized. Of each oligonucleotide, 125 ng and 50 ng of double-stranded Ϫ165 hUCP3-Luc were incubated with 2.5 U of PfuTurbo DNA polymerase. PCR was done for 17 cycles at 95 C for 30 sec, 55 C for 1 min, and 68 C for 14 min. Then, 10 U of DpnI restriction enzyme were added to each PCR and incubated at 37 C for at least 1 h to digest parental DNA. One microliter of the DpnI-treated DNA was then transformed. To generate point mutations, the oligonucleotides used were: for the Ebox mutation (Ϫ165mutEboxhUCP3-Luc) 5Ј-GCCAGCCTCTTGTCcAtg-GATCAGGCTGTC-3Ј (introducing a NcoI restriction site); for mutation of one half-site of the DR-1 (Ϫ1588mut1DR1 hUCP3-Luc and Ϫ 165mut1DR1 hUCP3-Luc) 5 Ј - restriction site) ; for the mutation of the other half-site of the DR-1 (Ϫ165mutDR1 hUCP3-Luc) 5Ј-CCAACTTCTCTAGGATAAacgTTCAGGT-CAGCCCGTGTG-3Ј (introducing an AclI restriction site); to study the presence of C instead of T according to the polymorphism described in the promoter, (Ϫ165mutC/T: 5Ј-GGTTTCAGGTCACCcGTGTGTATAAGACCAGTGC-3Ј; to mutate the three CA close to the transcription start site, 5Ј C C A G T G C C A A G C t t G A A G t t G C A G A G A t t A C A G T G -AATGACAAGGAGGG-3Ј (introducing a HindIII restriction site). To generate pCMV-MyoD-RRR (change of Lys 99, 102, and 104 to Arg) the oligo used was 5Ј-GGGCCTGCAgGGCGTGCAgGCGCAgGACCACCAACG-3Ј. Pointmutated constructs were checked by direct DNA sequencing. The plasmid Ϫ60 hUCP3-Luc was generated from mut1DR1 hUCP3-Luc by digestion with KpnI and NdeI, bluntending, and ligation.
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Cell Culture and Transient Transfection Assays
Myoblastic L6 cells were obtained from American Type Culture Collection (Manassas, VA) and were grown in DMEM containing 10% fetal bovine serum (FBS). Human skeletal muscle cells obtained from normal human tissue were purchased from Cambrex (Verviers, Belgium) and were grown in the culture medium provided by the supplier (Skeletal Muscle Cell Growth Medium Bullet Kit). Transfection experiments were carried out in L6 or human skeletal muscle cells at 50% confluence by using FuGene6 Transfection Reagent (Roche Diagnostics Applied Science, Barcelona, Spain) and were performed according to the manufacturer's instructions. For L6 transfection each point was assayed (unless indicated) in triplicate in a six-well plate and contained 1.5 g of luciferase reporter vector, 0.3 g of the mammalian expression vectors pCMV-MyoD (41), pSG5-PPAR␣, pSG5-PPAR␦, pSG5-PPAR␥ (42-44), pCMV-p300 and pCMV-p300⌬HAT (45), pcM/HDAC-1 (31), pcx-P/CAF (46), Tat-interactive protein-60 kDa (47) and pcDNA3-SRC1 (48) expression vectors, and 3 ng of pRL-CMV (Promega Corp., Madison, WI), an expression vector for the sea pansy (Renilla reniformis) luciferase used as an internal transfection control. Cells were incubated for 48 h after transfection and, when indicated, were treated for 24 h before harvest with or without 10 M Wy14,643, 100 M bezafibrate, 10 M Rosiglitazone, 500 M oleic acid, and 500 M linoleic acid. TSA treatment was performed at 100 ng/ml for 24 h. For assays of the activity of apoAII-PPRETKpGL3 (a gift of Dr. L. Fajas), the same conditions were used but including only 0.25 g luciferase reporter vector.
Firefly luciferase and Renilla luciferase activities were measured in a Turner Designs Luminometer (model TD20/20) using the Dual Luciferase Reporter assay system kit (Promega Corp.). Homogenates from cells were prepared with 500 l of PLB (passive lysis buffer, Promega Corp.). Cells were lysed in agitation for 15 min and homogenate (20 l) was used for measurement. Luciferase activity elicited by UCP3 promoter constructs was normalized for variation in transfection efficiency using Renilla luciferase as an internal standard. 
Western Blot Analysis
Nuclear extracts were obtained as described (49) . Protein (20 g) was mixed with 2ϫ sodium dodecyl sulfate (SDS) loading buffer, incubated at 90 C for 5 min, and subjected to SDS-PAGE (12% wt/vol). Proteins were transferred to polyvinylidine difluoride membranes and immunological detection was performed with specific antibodies against PPAR␣, PPAR␦, or PPAR␥ (Santa Cruz Biotechnology, Inc; no. sc-9000; no. sc-1987; and no. sc-7196, respectively). Detection was achieved by the enhanced chemiluminescence detection system (ECL; Amersham Pharmacia Biotech).
Somatic Gene Transfer via im DNA Injections
Direct injection of plasmid DNA to neonatal hind limb muscles was performed essentially as reported previously (50) . All plasmids were purified using QIAGEN (Chatsworth, CA) columns and resuspended in NaCl (0.9% vol/vol). DNA concentrations were quantified by spectrophotometry at 260 nm. Each firefly luciferase reporter plasmid (100 g) was mixed with 10 g of pRL-CMV and directly injected into the hind limb leg muscle of neonatal Swiss mice before initiation of suckling. Wild-type construct (Ϫ1588 hUCP3-Luc) was injected to one hind limb and the mutated version (Ϫ1588mutDR1 hUCP3-Luc) to the other. Neonates were kept with their mothers for 72 h and total muscle from every hind limb was collected and homogenized with a Polytron in 500 l of PLB buffer and analyzed for firefly and Renilla luciferase activity as described previously.
EMSAs
Nuclear protein extracts from L6 cells and from Swiss mice gastrocnemius muscle were isolated as reported previously (51, 52) , and protein concentration was determined by the micromethod of Bio-Rad Laboratories, Inc. (Richmond, CA) using BSA as standard. For gel retardation assays, the doublestranded UCP3-DR1 oligonucleotide corresponding to the Ϫ79 to Ϫ50 sequence of the UCP3 gene was end-labeled using [␣ 32 P]dCTP and Klenow enzyme. The DNA probe (25,000 cpm) was incubated for 30 min at 25 C with 5 g of nuclear protein extract. Reactions were carried out in a final volume of 25 l containing 20 mM HEPES (pH 7.6), 0.1 mM EDTA, 1 mM dithiothreitol, 50 mM NaCl, 10% glycerol, and 2.5 g of poly dI.dC (deoxyinosinic-deoxycytidylic acid). Samples were analyzed by electrophoresis at 4 C for 60-80 min in nondenaturing 5% polyacrylamide gels in 0.5ϫ Tris-borate-EDTA. In the competition experiments, 100-fold molar excess of unlabeled doublestranded oligonucleotides was included in each respective binding reaction. When indicated 2 l of antisera against PPAR␣ (Santa Cruz no. sc-9000) or C/EBP␣ (Santa Cruz no. sc-9314) was added to the incubation media for 15 min. The reactions including recombinant MyoD (Santa Cruz, no. sc-4080) were carried out in 25 mM HEPES (pH 7.5), 0.5 mM dithiothreitol, 50 mM KCl, 5% glycerol, 12.5 M ZnSO 4, 0.1% Nonidet P-40, 1 mg/ml BSA, 50 g/ml poly dI.dC, and 300 ng MyoD.
ChIP Assay
Human skeletal muscle cells were transfected or not with MyoD expression vector. L6 cells were transfected with Ϫ165 hUCP3-Luc or Ϫ165mutCAhUCP3-Luc in the presence of MyoD expression vector. Protein-DNA cross-linking was achieved by adding formaldehyde (final concentration 1%) to the culture medium for 10 min at 37 C. The cells were washed twice with cold PBS containing 1 mM phenylmethylsulfonyl fluoride, 1 g/ml aprotinin, and 1 g/ml pepstatin A (protease inhibitors). Cells were then scraped in PBS, centrifuged, and resuspended in 0.2 ml cell lysis buffer [5 mM PIPES (KOH) (pH 8.0), 85 mM KCl, 0.5% (vol/vol) Nonidet P-40 plus the protease inhibitors]. Samples were incubated on ice for 10 min and centrifuged for 10 min at 4 C. Pellets were resuspended in 0.2 ml SDS buffer [1% SDS, 10 mM EDTA, 50 mM Tris-HCl (pH 8.1), plus the protease inhibitors] and incubated on ice for 10 min. The samples were sonicated and centrifuged for 10 min at 4 C, and supernatants were diluted 10-fold with immunoprecipitation dilution buffer [0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl (pH 8.1), 167 mM NaCl plus the protease inhibitors]. To reduce nonspecific binding, samples were incubated at 4 C for 1 h, with 80 l of protein G-sepharose slurry as 50% suspension Tris-EDTA, which was pretreated with salmon sperm DNA.
Precleared chromatin solutions were incubated overnight at 4 C with 20 g of anti-MyoD antibody (Santa Cruz, no. sc-760) or an equal amount of an unrelated immunoglobulin (Santa Cruz no. sc-9314). The immunocomplex was then collected by binding to 60 l protein G-sepharose slurry as before. After incubation for 1 h at 4 C, the sepharose beads were collected by centrifugation, subsequently washed with 1 ml low-salt buffer [0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.1), 150 mM NaCl], high-salt buffer [0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.1), 500 mM NaCl], LiCl buffer [0.25 M LiCl, 1% Nonidet P-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl (pH 8.1)], and twice with Tris-EDTA. The complexes were eluted by two successive 15-min incubations with 250 l of elution buffer (1% SDS, 0.1 M NaHCO 3 ) at room temperature. The pooled eluates were heated to 65 C for 4 h in the presence of 20 l NaCl (5 M), to reverse the formaldehyde cross-links and then treated with proteinase K for 1 h at 45 C. After phenolchloroform extraction, DNA was used for PCR analysis. ChIP analysis of acetyl-histone H3 was performed using the reagents (Acetyl-Histone H3 Immunoprecipitation, ChIP, Assay Kit) from Upstate Biotechnology, Inc. (Lake Placid, NY) and following the specific instruction from the supplier. Input sample corresponds to cleared chromatin before immunoprecipitation with the antiacetylated histone H3 antibody.
Primers for amplifying a 191-bp fragment encompassing the noncanonical Eboxes of the human UCP3 promoter were forward 5Ј-GATCTGGAACTCACTCACC-3Ј and reverse 5Ј-CAGCAGGGATTGGATGGC-3Ј and those amplifying a 620-bp fragment of the human cyclophilin A gene, used as a control, were forward 5Ј-GTGTACTATTAGCCATGGTCAA-CCC-3Ј and reverse 5Ј-CTGCAGCGAGAGCACAAAGAT-TCT-3Ј. After 35 cycles of amplification, PCR products were electrophoresed in a 1.5% agarose gel and visualized by ethidium bromide staining.
Statistical Analysis
Where appropriate, statistical analysis was performed by Mann-Whitney nonparametric U test; significance is indicated in the text.
